EZH2-IN-7

• Description:

  EZH2-IN-7 is a potent inhibitor of EZH2. EZH2 overexpression or mutations in the SET region (Y641F, Y641N, A687V, A677G point mutations) all lead to abnormal elevation of H3K27me3 and promote the growth and development of many types of tumors, such as breast cancer, prostate cancer, leukemia, etc. EZH2-IN-7 has the potential for the research of cancer diseases (extracted from patent WO2021129629A1, compound 259) [1].

• UNSPSC:

  12352005

• Target:

  Histone Methyltransferase

• Type:

  Reference compound

• Related Pathways:

  Epigenetics

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Solubility:

  10 mM in DMSO

• Smiles:

  CSC(C=C(NC1=O)C)=C1C([2H])([2H])NC(C2=C(C)N([C@@H](C3CCC(CC3)OC)C)C4=CC=C(C5=CN(C)N=C5)C=C24)=O

• Molecular Formula:

  C31H37D2N5O3S

• Molecular Weight:

  563.75

• References & Citations:

  [1] Li Yao, et al. Zeste enhancer homologue 2 inhibitor and its use. Patent WO2021129629A1.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  EZH2

• CAS Number:

  [2659225-28-0]